Erianin Suppresses Endometrial Cancer Progression by Regulating the miR-661/BOK Axis

Pang, Xuecheng; Zhang, Xiang; Huang, Yue; Qian, Sumin

doi:10.1007/s43450-021-00219-5

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with this, as MCL-1 expression is upregulated in some cancers, the possibility of BOK as a potential chemotherapeutic target might be considered, as recently proposed, for example, by disrupting its interaction with the MCL-1 TM domain (Sancho and Orzáez, 2021;Wen et al, 2019). This is supported by a study in which inhibition of the non-protein-coding RNA anti-miR-661, which suppresses BOK expression in endometrial cancer, caused increased BOK expression and reduced cancer growth (Pang et al, 2021). In contrast, it has been shown that BOK can also act as a tumour promoter, as BOKknockout (KO) lung cancer cells proliferated slower than BOKcontaining lung cancer cells (Meinhardt et al, 2022).…”

Section: Box 1 Multi-level Regulation Of Apoptosismentioning

confidence: 89%

Expanding roles of BCL-2 proteins in apoptosis execution and beyond

King,

Hohorst,

García-Sáez

2023

Journal of Cell Science

View full text Add to dashboard Cite

The proteins of the BCL-2 family are known as key regulators of apoptosis, with interactions between family members determining permeabilisation of the mitochondrial outer membrane (MOM) and subsequent cell death. However, the exact mechanism through which they form the apoptotic pore responsible for MOM permeabilisation (MOMP), the structure and specific components of this pore, and what roles BCL-2 proteins play outside of directly regulating MOMP are incompletely understood. Owing to the link between apoptosis dysregulation and disease, the BCL-2 proteins are important targets for drug development. With the development and clinical use of drugs targeting BCL-2 proteins showing success in multiple haematological malignancies, enhancing the efficacy of these drugs, or indeed developing novel drugs targeting BCL-2 proteins is of great interest to treat cancer patients who have developed resistance or who suffer other disease types. Here, we review our current understanding of the molecular mechanism of MOMP, with a particular focus on recently discovered roles of BCL-2 proteins in apoptosis and beyond, and discuss what implications these functions might have in both healthy tissues and disease.

show abstract

Section: Box 1 Multi-level Regulation Of Apoptosismentioning

confidence: 89%